Ophthalmological pharmacology has historically lacked systematic understanding of disease mechanisms, especially of those for the back of the eye. This is now changing with the discovery of novel targets and pathways paired with a greater understanding of the role of genetics in ocular pathologies.

The third annual Targeting Ocular Disorders will cover some of the most promising emerging therapies in the treatment of ocular diseases. Special focus with be given to age-related macular degeneration and retinopathy. Designated sessions will emphasize of the role of precise imaging techniques and animal models in accelerating preclinical development. Recent solutions in drug delivery to the back of the eye will also be discussed.

Preliminary Agenda


New Horizons for Glaucoma Therapy

Naj Sharif, Ph.D., Director, Pharmacology & Imaging; Global Regulatory Affairs, Alcon, a Novartis Company

Nitric Oxide-cGMP Signaling as a Therapeutic Target for Glaucoma

Emmanuel Buys, Ph.D., Assistant Professor, Anesthesia, Harvard Medical School; Associate Scientist, Broad Institute of MIT and Harvard

Interleukin-1 Receptor Antagonist Drug for Treatment of Inflammatory Diseases

Eric Furfine, Ph.D., CSO, Eleven Biotherapeutics

Characterization of a CrossMAb Antibody Targeting VEGF and Ang2 for Neovascular Diseases of the Eye

Guido Hartmann, Ph.D., Senior Principal Scientist, Neurology, Ophthalmology and Rare Disease DTA; Laboratory Head, Research and Early Development, F. Hoffmann-La Roche

Nuclear Receptors as Therapeutic Targets for Age-Related Macular Degeneration

Goldis Malek, Ph.D., Associate Professor, Ophthalmology, Duke University School of Medicine

Topical, Beta-Adrenergic Agonist as Novel Approach to Treat Diabetic Macular Edema and Retinopathy (DMER)

Robert Ferry, Ph.D., Professor, Pediatrics, University of Tennessee Health Science Center

Panel Discussion: Dry AMD under Attack
Moderator: David Sherris, Ph.D., CSO, RestorGenex, Inc.

Elias Reichel, M.D., Professor, Ophthalmology, Tufts University School of Medicine; Co-Founder, Hemera Biosciences, Inc.


Utility of in vivo Confocal Microscopy-Based Imaging Endpoints for the Assessment of Ocular Surface Inflammation

Pedram Hamrah, M.D., Assistant Professor, Ophthalmology, Harvard Medical School; Director, Ocular Surface Imaging Center, Massachusetts Eye and Ear Infirmary

Using OCT as a Biomarker in Disease

Jay S. Duker, M.D., Professor and Chair, Ophthalmology, Tufts University School of Medicine; Director, New England Eye Center


Challenges and Advances in Macromolecular Delivery to the Back of the Eye

Cindy Wu, Ph.D., Principal Scientist, Pharmaceutical Sciences, Allergan, Inc.

Long Acting Delivery of Antibody Therapeutics to the Back of the Eye

Robert Kelley, Ph.D., Senior Scientist, Drug Delivery, Genentech, Inc.


Talk Title to be Announced

Donald Jeffrey Zack, M.D., Professor, Genetic Engineering & Molecular Ophthalmology; Professor, Ophthalmology; Professor, Neuroscience, Johns Hopkins Medicine

Targeting the Inflammasome Signaling in a Mouse Model of Geographic Atrophy: A Gene Therapy Approach

Cristhian J. Ildefonso, Ph.D., Senior Postdoctoral Associate, Laboratory of Dr. Alfred S. Lewin, Molecular Genetics & Microbiology, University of Florida College of Medicine

For questions or suggestions about the meeting, please contact:
Amid Zand
Associate Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-1346
E: azand@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 


Part Of DOT